L'Oréal USA Settles First Hair Relaxer Cancer Trial in Chicago

L'Oréal USA has settled, for an undisclosed sum, the first hair relaxer cancer claims ever to reach trial — resolving lawsuits brought by four women in Cook County, Illinois, who alleged that prolonged use of chemical hair straightening products caused their gynaecological cancers.
The trial opened on 9 November 2026. The settlement, reached mid-proceeding, ends the claims of the four plaintiffs but establishes no liability and leaves the wider litigation very much alive.
How big is the remaining litigation?
More than 12,700 related cases are currently consolidated before a federal judge in Chicago. The four Illinois cases were the first anywhere in the United States to make it to a jury, making this settlement a template-setting moment for how manufacturers handle the backlog behind it.
The products at issue were marketed under brands including Dark & Lovely and Optimum — lines that have historically targeted consumers with textured hair. Several other hair care manufacturers were defendants alongside L'Oréal USA in the Cook County proceedings.
What does the science say?
The litigation traces back to a 2022 National Institutes of Health study that identified an association between frequent chemical hair straightener use and an increased risk of uterine cancer. Note the framing: an association, not established causation.
L'Oréal has leaned on exactly that distinction. The company maintains that its products comply with applicable regulations and undergo rigorous safety assessments, and it disputes claims that the NIH research establishes a causal relationship between its relaxers and cancer diagnoses.
What does this change for manufacturers?
Practically, three things stand out from the source record:
- The settlement resolves four claims at a confidential amount, but does not settle liability questions for the 12,700-plus federal cases behind them.
- L'Oréal separately faces lawsuits filed by the states of Arizona and Minnesota over allegations concerning product safety disclosures — meaning the company's legal exposure runs through state courts as well as the federal multidistrict docket.
- The proceedings spotlight ingredient safety, product testing, regulatory compliance and historical marketing practices as the four pressure points now driving legal and financial risk across the US hair care industry.
For dermatology and cosmetics stakeholders, the mechanism matters as much as the outcome. Plaintiffs built claims on epidemiological association data — the same evidence class clinicians weigh when counseling patients on relaxer use. A mid-trial settlement doesn't test that evidence under cross-examination, which keeps the scientific question legally unresolved even as it raises the financial stakes for every pending defendant.
The deal also signals how companies may now price settlement versus trial risk across their hair care portfolios. With the first trial settled rather than verdict-decided, manufacturers watching the Chicago docket have no precedent number — either for damages or for defense success — to anchor their own calculus.
Whether future defendants settle early or take their chances before a jury will depend on how the next cases to reach trial perform, and on whether the NIH association holds up under the stricter causation standard a courtroom demands.
Source: globalcosmeticsnews.com
Olivia Hart
Show full bio
News editor covering technology and product news in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.